STING1 and cancer: However, in VEGF‐rich cancers, VEGF/VEGFR2 signaling might hamper the antitumor efficiency of STING agonists due to its negative regulation of type I IFN signaling activation via ubiquitin‐mediated IFN α and β receptor (IFNAR) degradation.292, 293